Delay of appropriate antibiotic treatment is associated with high mortality in patients with community-onset sepsis in a Swedish setting

Maria Andersson1 · Åse Östholm-Balkhed1 · Mats Fredrikson2,3 · Martin Holmbom1,4 · Anita Hälgren1 · Sören Berg5 · Håkan Hanberger1

Received: 10 December 2018 / Accepted: 1 March 2019 / Published online: 25 March 2019 © The Author(s) 2019

Abstract
Early appropriate antimicrobial therapy is crucial in patients with sepsis and septic shock. Studies often focus on time to first dose of appropriate antibiotics, but subsequent dosing is equally important. Our aim was to investigate the impact of fulfillment of early treatment, with focus on appropriate administration of first and second doses of antibiotics, on 28-day mortality in patients with community-onset severe sepsis and septic shock. A retrospective study on adult patients admitted to the emergency department with community-onset sepsis and septic shock was conducted 2012–2013. The criterion “early appropriate antibiotic treatment” was defined as administration of the first dose of adequate antibiotics within 1 h, and the second dose given with less than 25% delay after the recommended dose interval. A high-risk patient was defined as a septic patient with either shock within 24 h after arrival or red triage level on admittance according to the Medical Emergency Triage and Treatment System Adult. Primary endpoint was 28-day mortality. Of 90 patients, less than one in four (20/87) received early appropriate antibiotic treatment, and only one in three (15/44) of the high-risk patients. The univariate analysis showed a more than threefold higher mortality among high-risk patients not receiving early appropriate antibiotic treatment. Multivariable analysis identified early non-appropriate antibiotic treatment as an independent predictor of mortality with an odds ratio for mortality of 10.4. Despite that the importance of early antibiotic treatment has been established for decades, adherence to this principle was very poor.

Keywords Sepsis · Septic shock · Antibiotics · Mortality · Emergency department

Introduction
Sepsis and septic shock are common causes of mortality and morbidity in Sweden and globally. The reported annual incidence of sepsis varies depending on the method used to identify cases, but estimates of sepsis and septic shock rates lie around 500/100,000/year and 30–50/100,000/year, respectively [1–7].

Early recognition with resuscitation [8] and appropriate antibiotic treatment is known to be crucial for survival. Delayed appropriate antibiotic treatment has been shown to be an independent risk factor for mortality both in severe sepsis and septic shock [9–15], a fact that was confirmed in a recent systematic review of the literature [16].

Time to first antibiotic has been well studied, but administration of subsequent doses has received less attention. However, Leisman et al. [17] found that a major delay (> 25%) of the second dose was associated with increased
hospital mortality. This is supported by pharmacokinetic/
pharmacodynamic (PK/PD) studies showing that optimising
antibiotic administration may increase survival [18–20].

The Surviving Sepsis Campaign Guidelines recommends
broad-spectrum antibiotics within 1 h after detection as a part
of the treatment bundle [21]. We are unaware of any treatment
bundle including subsequent dosing. Consequently, less atten-
tion is paid to improving this in sepsis quality initiatives.

Our hypothesis was that early appropriate antibiotic treat-
ment, i.e. first and second antibiotic dose at the right time,
leads to improved outcome.

The aim of this study was to investigate the effect of early
treatment on 28-day mortality, with focus on appropriate ad-
ministration of first and second doses of antibiotic(s), in pa-
tients with community-onset severe sepsis and septic shock.

Materials and methods

Study design and settings

A retrospective, observational cohort study was conducted at
Linköping University Hospital, Sweden, from September 30,
2012, until September 30, 2013. All patients aged 18 years or
older with the International Classification of Disease ICD-
10SE diagnosis A 40 (bacteraemia caused by Streptococci),
A 41 (other bacteraemia), R65.1 (severe sepsis) or R57.2 (sep-
tic shock) [22] at discharge, cared for in the intensive care unit
(ICU) and the Departments of Infectious Disease and Acute
Internal Medicine including the medical high dependency
unit, were identified. We included only patients admitted to
these departments since they are specialised in caring for pa-
tients with community-onset severe sepsis or septic shock. Of
these, patients who met the criteria of community-onset (de-
fined as no hospitalisation within 30 days prior to admission)
severe sepsis or septic shock within 24 h after arrival at the
emergency department (ED) were included. Flowchart for in-
clusion and exclusion is shown in Fig. 1.

The study was performed in a tertiary care university hos-
pital which serves a primary population of 172,000, with no
other ED in the catchment area. Patients transferred from an-
other hospital were excluded.

Patients were only included once, i.e. the primary admis-
son with community-onset severe sepsis or septic shock with-
in the study period.

Data collection

All data and records were reviewed by the first author. Any
ambiguities concerning application of definitions or clinical
treatments were resolved within the study group consisting of
senior infectious disease consultants and an ICU physician. The
primary endpoint was 28-day mortality. Secondary outcomes
were achievement of “early appropriate antibiotic treatment”
and treatment goals at 1 and 6 h according to the Surviving
Sepsis Campaign (SSC) at the time, and the Swedish Society of
Infectious Diseases’ treatment goals [23, 24].

The following baseline characteristics were registered: gen-
der, age, weight, renal function (eGFR < 30 ml/min × m²) and
previously diagnosed comorbidity. Severity of disease was
assessed by Medical Emergency Triage and Treatment
System Adult (METTS) [25, 26], APACHE II score [27]
and SOFA score [28]. Indicators of appropriate early treatment
(resuscitation, antibiotic treatment and fulfilment of early
treatment goals (see definition below)), limitation of level of
care, ICU admission, length of stay, indicators of organ dys-
function, focus of infection, aetiology and 28-day mortality
were also registered.

APACHE II and SOFA scores were calculated from the
time of arrival at the emergency department. Laboratory pa-
rameters and vital signs were followed over the first 48 h
(exception made for CRP which was followed until 72 h after
admission).

Antibiotic administration data recorded were as follows:
agent(s), dose, time of administration of first and second doses
of appropriate antibiotic and recommended dose interval(s).

Definitions of appropriate and early antibiotic
treatment

1. Appropriate antibiotic treatment: The following major
criteria had to be fulfilled:

(a) Treatment with antibiotic agent(s), including dose and
dose interval according to the national treatment guide-
lines [24]
(b) Susceptibility of the pathogen(s) isolated to the agent(s)
used (if the patient had a culture-negative sepsis only “a”
had to be fulfilled) [11]

2. Early appropriate antibiotic treatment

To fulfil the definition of early appropriate antibiotic treat-
ment, the 1st dose fulfilling the major criteria had to be ad-
ministered within 1 h, and the 2nd dose fulfilling the major
criteria given with less than 25% delay based on the recom-
mended dose interval in the national treatment guidelines.

In cases of uncertainty, evaluation of the appropriateness of
antibiotic treatment was discussed in the study group
consisting of senior infectious disease consultants and an
ICU physician.

The timing of the 2nd dose of an appropriate antibiotic with
renal elimination took into consideration the increased dose
interval due to reduced renal excretion. When more than one
adequate antibiotic was given, the longest recommended dose
interval was applied [17]. The ratio for time interval between
the first and second doses was calculated as the actual time divided by the recommended time interval. For patients not receiving effective antibiotic therapy within 24 h, time to second dose and 1st-to-2nd dose interval ratio was not calculated.

**Treatment goals and resuscitation**

Treatment goals for the first hour were systolic blood pressure > 90 mmHg and oxygen saturation > 93%. Goals within 6 h were urinary production > 0.5 ml/kg/h, fall in lactate level and mean arterial pressure (MAP) ≥ 65 mmHg [23, 24].

Fluid resuscitation was recorded as type and amount of fluid given in the time intervals 0–2 h, 2–6 h and 6–24 h. Since the composition of the fluid therapy (crystalloids, colloids and blood products) varied between patients, the predicted intravascular volume expansion was calculated in order to compare the effect of fluids administered. Taking into account their extravascular distribution, crystalloid volume was multiplied by a factor of 0.25, albumin solutions 40–50 mg/ml by a factor of 0.5, albumin solutions 200 mg/ml by a factor of 1.5, plasma by a factor of 0.5 and blood transfusion by a factor of 1. Glucose infusion given slowly for calorific purposes was not included in the fluid calculations.

**Limitation of level of care**

For some of the patients included, the decision was made to limit the level of care. As such a decision influences both treatment given and mortality, this was a potential confounding factor. Limitation of level of care set within the first 24 h was registered as withholding: (a) ICU, (b) ventilator support, (c) dialysis, (d) cardiopulmonary resuscitation (CPR) and (e) withdrawal of all active treatment.

**Definitions of sepsis, high-risk patient, infection and focus of infection**

This study was performed prior to the introduction of the new sepsis definitions, Sepsis-3 [29], and hence, definitions according to the SSC criteria of 2012 were used [23].

**Sepsis:** The systemic inflammatory response (SIRS) to infection [30].

**Severe sepsis:** Sepsis with hypotension (systolic blood pressure (SBP) < 90 mmHg or MAP < 70 mmHg), hypoperfusion (P-lactate > 1 mmol/l above reference (3.4 mmol/l), base excess (BE) ≤ −5 mmol/l) or one or more of the following organ dysfunctions: renal (oliguria < 0.5 ml/kg/h ≥ 2 h despite resuscitation, or serum creatinine elevated > 45 μmol above the patient’s former value if known), respiratory (PaO2/ FiO2 < 33 kPa without or < 27 kPa with pneumonia), coagulation defect (platelet count < 100 × 109/l, PT-INR > 1.5 or APTT > 60s), CNS (altered mental status) or hepatic (S-bilirubin > 45 μmol/l).

**Septic shock:** Severe sepsis with sepsis-induced hypotension unresponsive to fluid resuscitation, together with hypoperfusion or organ dysfunction [3, 23, 30].

**High-risk patient:** Patients with red triage level according to METTS on arrival at the ED, or patients with septic shock on admission or shock within 24 h after arrival at the ED. Red triage level according to METTS is defined as a life-threatening condition requiring immediate medical attention by a physician. This identifies a more severely ill cohort of severe sepsis patients where more prompt treatment on the ED
might have prevented progress to shock. Thus, the combination resulting in the high-risk patient definition better identifies the population of severely ill septic patients.

**Infection sites:** The definitions suggested by the International Sepsis Forum Consensus Conference on Definitions of Infections in the Intensive Care Unit [31] were used, with minor changes.

**Bloodstream infection (BSI):** Isolation of bacteria or fungi from at least one blood culture. Microorganisms typically belonging to skin flora were considered a contamination.

**Pneumonia:** Symptoms and radiology indicating pneumonia.

**Urosepsis:** Positive culture from blood or two of the following: fever >38 °C, symptoms of UTI, relevant pathogens in the urine or radiographic evidence.

**Skin and soft tissue infection:** Erysipelas, cellulitis, fasciitis or wound infection.

**Intra-abdominal infection:** Symptoms and radiologic evidence, or findings during surgery of intra-abdominal infection. In case of surgery, positive blood cultures were required prior to surgery.

**Infective endocarditis:** Definite infective endocarditis according to the modified Duke criteria [31, 32].

**Microbiological aetiology:** Detection of relevant pathogens in cultures, by antigen testing or PCR technique.

**Community-onset:** No hospitalisation within 30 days prior to admission.

**Statistical analyses**

The primary outcome variable was 28-day mortality. The whole study group was analysed as such, and a subgroup analysis of high-risk patients was made. The statistical programs STATA v15 and SPSS version 24 were used for the analyses. We compared normally distributed quantitative variables with the *t* test and categorical variables using the chi² test or Fisher exact test. Mann–Whitney *U* test was used for fluid volumes. Double-sided *P* values were used. A *P* value < 0.05 was considered statistically significant. Missing data were treated by pairwise deletion, and there was no imputation. A multivariable analysis was performed with logistic regression including the univariate parameters correlating to 28-day mortality followed by stepwise removal of parameters.

**Results**

**Characteristics of the study population**

There were 90 patients enrolled in the study, mean age was 73 years and 51% were female. Overall 28-day mortality was 26.7%. Baseline characteristics are shown in Table 1. Sixty-three patients had severe sepsis without shock and 27 patients developed shock within 24 h, with mortality rates of 17.5% and 48.2%, respectively. There were no differences in age or gender regarding the risk for developing septic shock (data not shown).

Significantly increased mortality in the total study population was associated with higher age, presence of shock or being a high-risk patient (see below), higher maximum lactate level, respiratory and renal dysfunction due to the infection and number of dysfunctional organs.

A subgroup analysis was made on high-risk patients (patient with red triage level according to METTS in the ED or shock within 24 h after arrival at the ED) (Table 1).

Clinical interventions and treatment evaluations are shown in Table 2. Limitation of level of care and failure to achieve haemodynamic stability within 6 h (MAP ≥ 65 mmHg within 6 h) were associated with increased mortality. More extensive fluid administration late in the course (6–24 h) was also related to higher mortality. Twenty-four patients were treated for sepsis on the ICU at some time during their hospital stay. The 28-day mortality rate was 38% among ICU-treated patients (9/24) and 23% (15/66) among patients treated on the general ward or intermediate care unit. This difference, however, was not significant.

During the first 24 h, 26% (23/90) of the patients had their level of care limited, and their mortality rate was 56.5%. Typical for this group were increased age, presence of congestive heart failure, higher APACHE II score and an increased number of failing organs due to infection. These patients received more fluid between 6 and 24 h, but there were no other significant differences regarding clinical interventions. Data on this are presented in the supplementary files. When excluding patients with care limitation, mortality in the study population was 16% (11/67) and in the high-risk group 17% (5/30).

**Focus of infection, microbiological diagnosis**

Urinary tract infection (UTI) followed by pneumonia, skin and soft tissue infection (SSI) and infection of unknown origin were the most common foci (Table 3). Mortality was highest among patients with unknown focus (7/12). Blood cultures were obtained from all but two patients, but only 50% were positive. A culture-confirmed focus of infection was found in 73% (66/90) of patients, and 79% (71/90) had a microbiological diagnosis (based on cultures, antigen testing or PCR technique) (Table 4).

The most common pathogen was *Escherichia coli* (*E. coli*) (23% of the patients), followed by *Streptococcus pyogenes* (10%). The frequency of *Staphylococcus aureus* (*S. aureus*) was only 7% (6/90), with a mortality of 67%, although based on very few cases. Two patients were treated for sepsis caused by *extended spectrum beta lactamase-producing Enterobacteriaceae* (ESBLs) and one patient for sepsis due to *Streptococcus pneumoniae* with reduced susceptibility to
|                          | Total study population |                              | High-risk patients |                              |                              |                          |
|--------------------------|------------------------|------------------------------|-------------------|------------------------------|------------------------------|--------------------------|
|                          | Survivors ($n = 66$)   | Non-survivors ($n = 24$)     | $P$ value         | Survivors ($n = 29$)         | Non-survivors ($n = 17$)     | $P$ value               |
| Age (years) (SD)         | 70 (15)                | 83 (9)                       | < 0.001           | 68 (15)                      | 83 (11)                     | 0.001                   |
| Female sex (%)           | 35 (53)                | 11 (45.8)                    | 0.546             | 15 (51.7)                    | 8 (47.1)                    | 0.76                    |
| Preexisting comorbidity (%) |                       |                              |                   |                              |                              |                          |
| Malignancy, all          | 6 (9.1)                | 5 (20.8)                     | 0.154             | 3 (10.3)                     | 4 (23.5)                    | 0.397                   |
| Metastatic malignancy    | 1 (1.5)                | 3 (12.5)                     | 0.056             | 1 (3.4)                      | 2 (11.8)                    | 0.545                   |
| Haematological malignancy| 3 (4.5)                | 1 (4.2)                      | 0.999             | 2 (6.9)                      | 1 (5.9)                     | 0.999                   |
| Diabetes mellitus        | 14 (21.2)              | 6 (25)                       | 0.702             | 5 (17.2)                     | 4 (23.5)                    | 0.707                   |
| Congestive heart failure | 8 (12.1)               | 6 (25)                       | 0.187             | 2 (6.9)                      | 4 (23.5)                    | 0.174                   |
| Immunosuppression, any   | 19 (28.8)              | 5 (20.8)                     | 0.450             | 10 (37.9)                    | 3 (17.6)                    | 0.315                   |
| Immunosuppression, > 10 mg Prednisolone | 9 (13.6)              | 0                             | 0.106             | 4 (13.8)                     | 0                            | 0.281                   |
| Chronic pulmonary disease| 8 (12.1)               | 5 (20.8)                     | 0.320             | 4 (13.8)                     | 4 (23.5)                    | 0.443                   |
| Chronic renal failure (GFR < 30) | 4 (6.1)                | 1 (4.2)                      | 0.999             | 1 (3.4)                      | 0                            | 0.999                   |
| Severity of disease      |                        |                              |                   |                              |                              |                          |
| APACHE II (SD)           | 19.0 (5.7)             | 21.4 (7.1)                   | 0.101             | 21.5 (4.8)                   | 23.6 (7.0)                  | 0.235                   |
| Maximum SOFA (SD)        | 5.2 (3.0)              | 6.3 (3.7)                    | 0.132             | 6.2 (3.4)                    | 7.4 (3.8)                   | 0.265                   |
| SBP < 90 mmHg/MAP < 65 mmHg (SD) | 57 (86.4)              | 19 (79.2)                    | 0.511             | 25 (86.2)                    | 15 (88.2)                   | 0.999                   |
| Septic shock (%)         | 14 (21.2)              | 13 (54.2)                    | 0.003             | 14 (48.3)                    | 13 (76.5)                   | 0.061                   |
| High-risk patients (%)   | 29 (43.9)              | 17 (70.8)                    | 0.024             | 29 (100)                     | 17 (100)                    | 0.003                   |
| Maximum lactate level day 1 (SD) | 2.4 (1.7) $n = 53$   | 4.4 (2.8) $n = 23$          | < 0.001           | 2.7 (1.7) $n = 28$          | 4.9 (2.9) $n = 17$          | 0.003                   |
| Number of organ dysfunction (SD) | 1.35 (1.0)            | 2.21 (1.4)                   | 0.002             | 1.7 (1.1)                    | 2.8 (1.3)                   | 0.006                   |
| Respiratory (%)          | 19 (28.8)              | 14 (58.3)                    | 0.010             | 13 (44.8)                    | 14 (82.4)                   | 0.013                   |
| Renal (%)                | 37 (56.1)              | 20 (83.3)                    | 0.018             | 20 (69.0)                    | 15 (88.2)                   | 0.172                   |
| Haematological/coagulopathy (%) | 14 (21.2)              | 8 (33.3)                     | 0.237             | 9 (31.0)                     | 8 (47.1)                    | 0.277                   |
| CNS (%)                  | 15 (22.7)              | 9 (37.5)                     | 0.161             | 8 (27.6)                     | 8 (47.1)                    | 0.181                   |
| Liver (%)                | 2 (3.0)                | 2 (8.3)                      | 0.288             | 0                            | 2 (11.8)                    | 0.131                   |

Data are presented as no. (%) or mean (SD) as indicated. The total study population and the high-risk patients are analysed separately. $t$ Test, Pearson chi$^2$ or Fisher’s exact test, as appropriate. $P$ values < 0.05 are shown in italics.
| Table 2 | Clinical interventions and treatment evaluation among survivors and non-survivors |
|---------|--------------------------------------------------------------------------------|
|         | Total study population | High-risk patients |
|         | Survivors (n = 66) | Non-survivors (n = 24) | P value | Survivors (n = 29) | Non-survivors (n = 17) | P value |
| Volume (ml), median (IQR) | | | | | | |
| Crystalloids 0–6 h | 2000 (2000–3000) | 2000 (1500–3500) | 0.888 | 3000 (2000–5000) | 3000 (2000–4000) | 0.430 |
| Plasma expansion 0–6 h | 500 (500–900) | 515 (500–1025) | 0.540 | 875 (500–1375) | 1000 (500–1150) | 0.839 |
| Crystalloids 6–24 h | 2000 (1000–3000) | 2200 (1000–3000) | 0.381 | 2000 (1000–4000) | 3000 (2000–4000) | 0.230 |
| Plasma expansion 6–24 h | 500 (250–910) | 842 (500–1337) | 0.027 | 625 (450–1230) | 1100 (705–1875) | 0.040 |
| Appropriate antibiotics within 1 h (%) | 19 (29.2) | 5 (22.7) | 0.555 | 15 (53.6) | 4 (25.0) | 0.066 |
| 2nd dose without > 25% delay (%) | 48 (84.2) | 18 (81.8) | 0.784 | 22 (84.6) | 13 (81.3) | 0.999 |
| Early appropriate antibiotic treatment (%) | 17 (26.2) | 3 (13.6) | 0.228 | 13 (46.4) | 2 (12.5) | 0.022 |
| ICU admission (%) | 15 (22.7) | 9 (37.5) | 0.161 | 10 (34.5) | 7 (41.2) | 0.650 |
| ICU admission from ED (%) | 5 (7.6) | 5 (20.8) | 0.123 | 5 (17.2) | 4 (23.5) | 0.707 |
| Limits of level of care (%) | 10 (15.2) | 13 (54.2) | < 0.001 | 4 (13.8) | 12 (70.6) | < 0.001 |
| Within 1 h: SBP > 90 mmHg (%) | 41 (75.9) | 12 (57.1) | 0.109 | 15 (57.7) | 6 (40.0) | 0.275 |
| Within 1 h: saturation > 93% (%) | 42 (82.4) | 12 (60.0) | 0.065 | 19 (76.0) | 8 (57.1) | 0.287 |
| Within 6 h: urinary production > 0.5 ml/kg (%) | 15 (53.6) | 6 (60.0) | 0.999 | 7 (46.7) | 4 (50.0) | 0.999 |
| Within 6 h: lowered lactate (%) | 9 (60.0) | 6 (46.2) | 0.464 | 6 (60.0) | 6 (50.0) | 0.691 |
| Within 6 h: MAP ≥ 65 mmHg (%) | 31 (53.4) | 5 (23.8) | 0.019 | 12 (48.0) | 2 (12.5) | 0.019 |

Data are presented as no. (%) or mean (SD) unless otherwise indicated. The total study population and the high risk patients are analysed separately. t Test, Pearson chi² or Fisher’s exact test, as appropriate. Volume calculated with Mann-Whitney U. P values < 0.05 are shown in italics.

SBP systolic blood pressure, MAP mean arterial pressure, BE base excess, SD standard deviation, ICU intensive care unit, SOFA sequential organ failure assessment, APACHE acute physiology and chronic health evaluation, ED emergency department
penicillin. There were no cases of methicillin-resistant *Staphylococcus aureus* (MRSA) or vancomycin-resistant Enterococci (VRE) (Table 5).

### High-risk patients

Mortality was 37% among the 46 high-risk patients. Higher age, maximum lactate level, number of failing organs and respiratory dysfunction due to infection were associated with increased mortality (Table 1).

Early appropriate antibiotic treatment and haemodynamic stability (MAP $\geq 65$ mmHg) within 6 h were associated with decreased mortality. Non-survivors received more intravenous fluid in the latter part of the course of the disease (6–24 h). Limitation of level of care was more common among non-survivors (Table 2).

### Antibiotic treatment

Data on antibiotic treatment are shown in Table 2. Twenty-four out of 87 patients received the first dose of appropriate antibiotic within 1 h (data regarding three patients were missing). In all, 23% (20/87) of the patients received early appropriate antibiotic treatment including 1st and 2nd doses. In the subgroup of high-risk patients, 34% (15/44) received early appropriate antibiotic treatment.

Of the 67 patients receiving inappropriate early antibiotic treatment, the main failure was delay of the first dose in 63 cases. Major delay of the second dose was found in 13/79 patients, and nine patients had a delay in the administration of both first and second doses. The majority received cefotaxime (60%) or piperacillin-tazobactam (16%), alone or in combination with another antibiotic. Carbapenems were used in 7%. No patient received vancomycin. Of the 71 patients with known aetiology, six patients received initial treatment with an antibiotic with inappropriate spectrum.

Among the high-risk patients, administration of early appropriate antibiotic treatment correlated to a lower 28-day mortality (Table 2).

### Risk factors for inappropriate antibiotic administration

Risk factors for delay of early appropriate antibiotic treatment (shown in Table 6) were lower triage level, lower disease severity (APACHE II and SOFA score) on arrival and administration of the first dose after transfer from the ED. Patients on immunosuppression received timely antibiotic treatment more frequently.

### Achievement of treatment goals

“Achievement of treatment goal” was a secondary outcome. For all patients, an oxygen saturation $> 93\%$ within 1 h and an established MAP $\geq 65$ mmHg within 6 h correlated with survival. Other treatment goals did not show any correlation with 28-day mortality, but data were missing in many cases (e.g. in 52/90 cases data were missing regarding urinary production within 6 h and in 62/90 cases regarding lactate level within 6 h).

---

### Table 3 Focus of infection among survivors and non-survivors

| Source of infection       | Frequency (%) | Survivors (n) | Non-survivors (n) | Mortality (%) | $P$ value |
|---------------------------|---------------|---------------|-------------------|---------------|-----------|
| Urinary (n = 33)          | 36.7          | 26            | 7                 | 21.2          | 0.37\textsuperscript{1} |
| Pulmonary (n = 23)        | 25.6          | 19            | 4                 | 17.3          | 0.24\textsuperscript{1} |
| Skin and soft tissue (n = 15) | 16.7       | 12            | 3                 | 25.0          | 0.52\textsuperscript{1} |
| Intra-abdominal (n = 4)   | 4.4           | 2             | 2                 | 50.0          | 0.29\textsuperscript{2} |
| Endocarditis (n = 2)      | 2.2           | 1             | 1                 | 50.0          | 0.46\textsuperscript{2} |
| Others (n = 1)            | 1.1           | 1             | 0                 | 0             | 0.99\textsuperscript{2} |
| Unknown (n = 12)          | 13.3          | 5             | 7                 | 58.3          | 0.01\textsuperscript{1} |

Data are presented no. (%). \textsuperscript{1} Pearson chi$^2$ or \textsuperscript{2} Fisher’s exact test. $P$ values $< 0.05$ are shown in italics.

---

### Table 4 Microbiological characteristics of survivors and non-survivors

|                      | Survivors (n = 66) | Non-survivors (n = 24) | $P$ value |
|----------------------|--------------------|------------------------|-----------|
| Positive blood culture | 30 (45.5)          | 15 (62.5)              | 0.161     |
| Any relevant culture  | 48 (72.7)          | 18 (75)                | 0.829     |
| Positive diagnostis   | 52 (78.8)          | 19 (79.2)              | 0.969     |

Data are presented as no. (%) Pearson chi$^2$ test. A $P$ value $< 0.05$ was considered statistically significant. There were no significant differences between the groups.
A multivariable analysis was performed on the high-risk patients (Table 7). At first, we included variables with a univariate correlation to 28-day mortality (age, maximum lactate level, number of dysfunctional organs, plasma expansion at 6–24 h, early appropriate antibiotic treatment, limit of level of care and MAP ≥ 65 mmHg within 6 h) within a logistic regression. Stepwise removal of the parameter with the highest P value rendered a three-variable model with the parameters age, early appropriate antibiotic treatment and limit of level of care giving the best fit.

The 28-day mortality was 46.4% among the high-risk patients who did not receive early appropriate antibiotic treatment compared with 12.5% among those who did (Table 2). This illustrates a more than threefold higher mortality rate among the high-risk patients who did not receive early appropriate antibiotic treatment (Table 2). In the multivariable analysis, inappropriate antibiotic therapy was found to be an independent predictor of mortality with an odds ratio for mortality of 10.4 in the high-risk group. The importance of timing and appropriateness of the first dose of antibiotics has been shown in previous studies, especially in septic shock [9–15, 33]. Leisman et al. studied the importance of timely administration of the 2nd dose and showed that major delay in the 2nd dose was associated with higher mortality [17]. Therapeutic antibiotic concentrations in blood and at the target site must be achieved and maintained as quickly as possible in order to reduce bacterial load [20]. Thus, adequate dose and dose intervals of antibiotics are crucial for improving prognosis. In retrospective material, timing of both first and second doses may be a marker of suboptimal initial treatment and improper pharmacokinetic adaptation. In the setting of this study, antibiotic treatment was usually initiated in the ED, followed by a transfer to the ward or ICU, making delay in the second dose a risk due to logistic reasons.

The importance of adequate dosing on survival is supported by PK/PD studies [18–20] and is even more important in the treatment of critically ill patients, due to more complicated pharmacokinetics [20, 34]. Change in distribution volume influences the plasma and tissue concentrations of water-soluble antibiotics, and glomerular filtration rate may be altered [18, 35] Tissue perfusion may be decreased, making it more difficult for the antibiotic to reach its target [36]. Antibiotic blood concentrations in the critically ill are often subtherapeutic [19, 34–36], and for that reason, therapeutic drug monitoring (TDM) is becoming more widespread [34]. This stresses the importance of adequate dosage, not only the first dose but also subsequent doses of the antibiotics, in order to achieve appropriate antibiotic exposure.

| Microbiological cause | Frequency (%) | Survivors (n = 66) | Non-survivors (n = 24) | Mortality % | P value |
|-----------------------|--------------|------------------|-----------------------|-------------|---------|
| **Gram-negative bacteria** |              |                  |                       |             |         |
| Escherichia coli      | 23           | 15               | 6                     | 29          | 0.82¹   |
| Klebsiella spp.       | 6            | 3                | 2                     | 40          | 0.61²   |
| Other Enterobactericeae | 7       | 4                | 0                     | 0           | 0.57²   |
| Pseudomonas aeruginosa | 2         | 2                | 0                     | 0           | 0.99²   |
| Neisseria meningitidis | 1         | 1                | 0                     | 0           | 0.99²   |
| **Gram-positive bacteria** |            |                  |                       |             |         |
| Streptococcus pyogenes | 10         | 7                | 2                     | 22          | 0.99²   |
| Streptococcus pneumoniae | 8        | 6                | 1                     | 17          | 0.67²   |
| Other Streptococcus spp. | 4         | 3                | 1                     | 25          | 0.99²   |
| Enterococcus faecalis | 3           | 3                | 0                     | 0           | 0.56²   |
| Staphylococcus aureus | 7           | 2                | 4                     | 67          | 0.04²   |
| Clostridium difficile | 1           | 1                | 0                     | 0           | 0.54    |
| Multiple pathogens    | 9           | 5                | 3                     | 38          | 0.47    |
| No positive diagnostics | 21         | 14               | 5                     | 26          | 0.97    |

Causative microbiological agent was based on cultures, antigen test and PCR methods. Data are presented as no. (%). ¹ Pearson chi², ² Fisher’s exact test. P values < 0.05 are shown in italics.

**Multivariable analysis**

A multivariable analysis was performed on the high-risk patients (Table 7). At first, we included variables with a univariate correlation to 28-day mortality (age, maximum lactate level, number of dysfunctional organs, plasma expansion at 6–24 h, early appropriate antibiotic treatment, limit of level of care and MAP ≥ 65 mmHg within 6 h) within a logistic regression. Stepwise removal of the parameter with the highest P value rendered a three-variable model with the parameters age, early appropriate antibiotic treatment and limit of level of care giving the best fit.

The 28-day mortality was 46.4% among the high-risk patients who did not receive early appropriate antibiotic treatment compared with 12.5% among those who did (Table 2). This illustrates a more than threefold higher mortality rate among the high-risk patients who did not receive early appropriate antibiotic treatment (Table 2). In the multivariable analysis, inappropriate antibiotic therapy was found to be an independent predictor of mortality with an odds ratio for mortality of 10.4 in the high-risk group.

**Discussion**

In this retrospective cohort of adult patients with severe sepsis and septic shock, we found in the univariate analysis a greater than threefold increase in mortality rate among high-risk patients not receiving early appropriate antibiotic treatment. In the multivariable analysis, inappropriate early antibiotic therapy was found to be an independent predictor of mortality with an odds ratio for mortality of 10.4 in the high-risk group.

The importance of timing and appropriateness of the first dose of antibiotics has been shown in previous studies, especially in septic shock [9–15, 33]. Leisman et al. studied the importance of timely administration of the 2nd dose and showed that major delay in the 2nd dose was associated with higher mortality [17]. Therapeutic antibiotic concentrations in blood and at the target site must be achieved and maintained as quickly as possible in order to reduce bacterial load [20]. Thus, adequate dose and dose intervals of antibiotics are crucial for improving prognosis. In retrospective material, timing of both first and second doses may be a marker of suboptimal initial treatment and improper pharmacokinetic adaptation. In the setting of this study, antibiotic treatment was usually initiated in the ED, followed by a transfer to the ward or ICU, making delay in the second dose a risk due to logistic reasons.

The importance of adequate dosing on survival is supported by PK/PD studies [18–20] and is even more important in the treatment of critically ill patients, due to more complicated pharmacokinetics [20, 34]. Change in distribution volume influences the plasma and tissue concentrations of water-soluble antibiotics, and glomerular filtration rate may be altered [18, 35] Tissue perfusion may be decreased, making it more difficult for the antibiotic to reach its target [36]. Antibiotic blood concentrations in the critically ill are often subtherapeutic [19, 34–36], and for that reason, therapeutic drug monitoring (TDM) is becoming more widespread [34]. This stresses the importance of adequate dosage, not only the first dose but also subsequent doses of the antibiotics, in order to achieve appropriate antibiotic exposure.
In the present study, 63/87 had a delay in the first dose making this the main failure, although this did not reach statistical significance with respect to mortality in our small material. Delay in the second dose itself had only a marginal effect on mortality. Since a large proportion of patients did not receive appropriate first dose antibiotics, evaluation of the effect of a delayed second dose alone is more difficult. When looking at the combination of inappropriate first and second doses, mortality was increased more than threefold in the high-risk group. This stresses the importance of adequate antibiotic exposure based on knowledge of PK/PD. In this respect, the timing of both first and second doses may be a marker for this approach.

In order to fulfil the criteria early appropriate antibiotic treatment, the antibiotic administered must have a spectrum of activity that covers the anticipated or confirmed pathogen(s). In our series, an antibiotic with too narrow spectrum was only found in 6 of the 71 patients with a confirmed pathogen, which may be explained by the low prevalence of antibiotic resistance in Sweden.

The high-risk patients gained most benefit from early appropriate antibiotic treatment; the challenge is thus to identify these patients at an early stage. In the high-risk group, 13/27 patients who developed shock within 24 h were not identified by METTS red triage level on admission to the ED. This difficulty stresses the importance of complying with early appropriate antibiotic regimes in all cases of suspected sepsis [9, 16]. In our study, the risk factors for inappropriate antibiotic treatment were mainly related to low APACHE II score or a low SOFA score and a low METTS triage level on arrival. There is, thus, a need for improvement in the early detection of sepsis in patients with subtle symptoms. This study also illustrates the importance of prompt re-establishment of haemodynamic stability, tissue perfusion and cellular metabolism. Achievement of the SSC haemodynamic goal of a MAP ≥ 65 mmHg within 6 h was associated with increased survival. These findings are consistent with previous studies [37, 38].

### Table 7

| Variable | OR (95% CI) | P value |
|----------|-------------|---------|
| Early appropriate antibiotic treatment | 0.096 (0.011–0.846) | 0.035 |
| Age | 1.077 (0.996–1.164) | 0.062 |
| Limitation of level of care | 8.684 (1.330–56.690) | 0.024 |

A logistic regression with 28-day mortality as dependent variable was performed. Stepwise removal of the parameter with the highest P value in the univariate analysis rendered a three-variable model with the parameters age, early appropriate antibiotic treatment and level of care giving the best fit. P values < 0.05 were considered statistically significant in the multivariable analysis and are shown in italics. To fulfil the criterion “early appropriate antibiotic treatment,” the 1st dose must have been adequate and administered within 1 h, and the 2nd dose given with less than 25% delay after the recommended interval.
Fluid therapy only differed between survivors and non-survivors in the latter part of the resuscitation period (6–24 h), where the non-survivors received more volume expansion. This probably reflects therapeutic efforts to restore haemodynamic stability in patients with prolonged circulatory failure not responding to initial fluid therapy, i.e. those with a poor prognosis. Maximum lactate level also correlated with mortality, illustrating the impact of disease severity, also seen in previous studies [39, 40].

The distribution of aetiologic pathogens and foci might have been influenced by the restricted inclusion material comprising patients from medical wards and the ICU only. *E. coli* was the most prevalent pathogen, which is in agreement with a previous study including all patients with bacteraemia in the same hospital [41]. *S. aureus*, on the other hand, was found in only six patients (7%). This incidence is lower than seen in many other studies (12–18%) based on positive blood cultures [2, 41, 42]. Our findings are supported by the National Register of Community-Acquired Sepsis of the Swedish Infectious Diseases Physicians Society, where *S. aureus* was the causing pathogen in 8–10% of cases during the same period of time [24]. The high mortality in the subgroup of *S. aureus* infections in our material (4/6) is deemed not to be representative but rather an effect of the small sample size. The prevalence of antibiotic resistance in Sweden is low, and our finding of a low level of resistant pathogens in this study is in line with Swedish resistance surveillance data [43].

Early antibiotic treatment was the main focus in this study, but data also revealed other important risk factors for mortality. Age, markers of severity of disease (maximum lactate level and number of dysfunctioning organs) and treatment (limited level of care, haemodynamic stabilisation, administration of fluids and antibiotics) were all correlated to mortality in the univariate analysis. All are known risk factors relating to outcome [39, 44–47]. The impact of treatment, including limit of level of care, is determined by the clinical management of the individual patient and thereby possible to modify in order to improve patient outcome. In the multivariable analysis, best fit was found for the model incorporating age, limited level of care and early appropriate antibiotic treatment as independent factors related to mortality. Patients with treatment limitation had, as might be expected, a higher mortality rate [46, 47]. This is an important factor to consider. Limitation of the level of care must be considered carefully since this may result in substandard care and increased morbidity and mortality if not applied correctly—fulfilment of the prophesy. In our study, those receiving limited care received more fluids in the latter part of the clinical period (6–24 h), which may have been the result of not being treated with inotropes. The mortality in the group that received limited care in our study was high, but we have no way of assessing the correctness of the restrictions applied. Whatever, care limitation must be thoroughly discussed and evaluated at the local level.

Even though our theoretical knowledge of sepsis treatment has improved over the last decade, there is much room for improvement in the practical management of the septic patient. Only 23% of patients with sepsis received early appropriate antibiotic treatment, and only 34% among obviously high-risk patients. This indicates shortcomings in the management of sepsis patients. Failure to achieve haemodynamic stability, seen as the lower number of patients with MAP > 65 mmHg at 6 h, also illustrates this point. Less than one in three patients with sepsis were treated on the ICU, even though more than half of the patients, in which treatment goals could be evaluated, were still not haemodynamically stable after 6 h.

This study has several limitations. It is a small, retrospective, single-centre study, making the results difficult to generalise. The distribution of aetiologic pathogens and infectious foci might have been influenced by the restricted inclusion material from medical wards and the ICU only. Some of the treatment goals were difficult to evaluate due to missing data.

Identification of septic patients using ICD-10 codes is also problematic and can lead to loss of cases as many patients lack specific sepsis codes at discharge [7]. Exclusion of patients who had been hospitalised within 30 days before admission also contributed to case loss.

This study also has strengths. The addition of sepsis criteria to the ICD-10 codes for inclusion resulted in a more well-defined study group. This is supported by Rhee et al., who found that sepsis based on clinical information increased the confidence in sepsis estimates, compared to identification by ICD-10 alone [5]. The use of both septic shock and METTS criteria resulted in a more precise identification of high-risk patients. Recruiting patients from medical wards and not just from the ICU better reflects the sepsis population in the Swedish healthcare system.

In conclusion, we found suboptimal initial management of septic patients at our hospital, with a more than threefold increase in mortality among high-risk patients not receiving early appropriate antibiotic treatment. Even though the importance of early antibiotic treatment has been established for a long time, adherence to this principle was very low. There is much room left for improvement in the early identification and appropriate antibiotic treatment of sepsis patients.

**Compliance with ethical standards**

The study was approved by the Ethics Review Board of Linköping University, Sweden (2013/466–31) and was performed in accordance with the Helsinki Declaration. The study was funded by the County of Östergötland.
Conflict of interest  The authors declare that they have no conflict of interest.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Mellhammar L, Wullt S, Lindberg A, Lanbeck P, Christensson B, Linder A (2016) Sepsis incidence: a population-based study. Open Forum Infect Dis 3(4):ofw207

2. Henriksen DP, Laursen CB, Jensen TG, Hallas J, Pedersen C, Lassen AT (2015) Incidence rate of community-acquired sepsis among hospitalized acute medical patients—a population-based survey. Crit Care Med 43(1):13–21

3. van Gestel A, Bakker J, Verraat CP, van Hout BA (2004) Prevalence and incidence of severe sepsis in Dutch intensive care units. Crit Care Med 8(4):R153–R162

4. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311(13):1308–1316

5. Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, Kadri SS, Angus DC, Danner RL, Fiore AE, Jermigan JA, Martin GS, Septimus E, Warren DK, Karcz A, Chan C, Menchaca JT, Wang R, Gruber S, Klompas M, Program CDCPE (2017) Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 318(13):1241–1249

6. Linder A, Gub D, Boyd JH, Walley KR, Anis AH, Russell JA (2014) Long-term (10-year) mortality of younger previously healthy patients with severe sepsis/septic shock is worse than that of patients with nonseptic critical illness and of the general population. Crit Care Med 42(10):2211–2218

7. Wilhelms SB, Walther SM, Huss F, Sjoberg F (2017) Sepsis severe in the ICU is often missing in hospital discharge codes. Acta Anaesthesiol Scand 61(2):186–193

8. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Program CDCPE (2001) Early goal-directed therapy in the treatment of patients with nonseptic critical illness and of the general population. Crit Care Med 39(2):165–174

9. Ferrer R, Martin-López E, Phillips G, Osborn TM, Townsend S, Dellinger RP, Artigas A, Schorr C, Levy MM (2014) Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 42(8):1749–1755

10. Kumar A, Haery C, Paladugu B, Kumar A, Szymoniak S, Taiberg L, Osman J, Trenholme G, Opal SM, Goldfarb R, Parrillo JE (2006) The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 193(2):251–258

11. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters C, Ahsan M, Chateau D, Cooperative Antimicrobial Therapy of Septic Shock Database Research G (2009) Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136(5):1237–1248

12. Lee CC, Lee CH, Chuang MC, Hong MY, Hsu HC, Ko WC (2012) Impact of inappropriate empirical antibiotic therapy on outcome of bacteremic adults visiting the ED. Am J Emerg Med 30(8):1447–1456

13. Nygard ST, Langeland N, Flaatten HK, Fanestil R, Haugen O, Skrede S (2014) Aetiology, antimicrobial therapy and outcome of patients with community acquired severe sepsis: a prospective study in a Norwegian university hospital. BMC Infect Dis 14:121

14. Puskarich MA, Trzeciak S, Shapiro NI, Arnold RC, Horton JM, Studnek JR, Kline JA, Jones AE, Emergency Medicine Shock Research N (2011) Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 39(9):2066–2071

15. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shover FS, Goyal M (2010) Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38(4):1045–1053

16. Sherwin R, Winters ME, Vilke GM, Wardi G (2017) Does early and appropriate antibiotic administration improve mortality in emergency department patients with severe sepsis or septic shock? J Emerg Med 53(4):588–595

17. Leisman D, Huang V, Zhou Q, Gribben J, Bianculli A, Bemshetey M, Ward MF, Schneider SM (2017) Delayed second dose antibiotics for patients admitted from the emergency department with sepsis: prevalence, risk factors, and outcomes. Crit Care Med 45(6):986–995

18. Blot SI, Pea F, Lipman J (2014) The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 77:3–11

19. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Study D (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58(8):1072–1083

20. Kumar A (2014) An alternate pathophysiological paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy. Virulence 5(1):80–97

21. Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43(3):304–377

22. Islas-Munoz B, Villanueva-Bernal, Ibanez-Gutierrez, Villamar-Ramirez A, Vilar-Compte D, Cornejo-Juarez P (2018) Bloodstream infections in cancer patients. Risk factors associated with mortality. Int J Infect Dis 71:59–64

23. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Lunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric S (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39(2):165–228

24. Seddon MM, Bookstaver PB, Justo JA, Rac H, Haggard E, Mediwala KN, Dash S, Al-Hasan MN (2018) Role of early escalation of antimicrobial therapy on risk of Clostridioides difficile infection following Enterobacteriaceae bloodstream infections. Clin Infect Dis

25. Widgren BR, Jourak M, Martinus A (2008) New accurate triage method. METTS-A yields basis for priority level decisions. Forum Infect Dis 3(4):ofw207

26. Widgren BR, Jourak M (2011) Medical Emergency Triage and Treatment System (METTS): a new protocol in primary triage

© Springer
and secondary priority decision in emergency medicine. J Emerg Med 40(6):623–628
27. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13(10):818–829
28. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22(7):707–710
29. Singer M, Deutschman CS, Wang S,ani R, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801–810
30. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101(6):1644–1655
31. Calandra T, Cohen J, International Sepsis Forum Definition of Infection in the ICUCC (2005) The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 33(7):1538–1548
32. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30(4):633–638
33. Seymour CW, Gny H, Friedrich ME, Iwashyna TJ, Phillips GS, Lemeshow S, Osborn T, Terry KM, Levy MM (2017) Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 376(23):2235–2244
34. Muller AE, Huttner B, Huttner A (2018) Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? Drugs 78(4):439–451
35. Huttner A, Von Dach E, Renzoni A, Huttner BD, Affatati M, Pagani L, Daali Y, Pugin J, Karmime A, Fathi M, Lew D, Harbarth S (2015) Augmented renal clearance in critically ill: an observational prospective cohort study. Int J Antimicrob Agents 45(4):385–392
36. Ullidemolins M, Roberts JA, Lipman J, Rello J (2011) Antibiotic dosing in multiple organ dysfunction syndrome. Chest 139(5):1210–1220
37. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garmacho-Montero J, Ibanez J, Palencia E, Quintana M, de la Torre-Prados MV, Edusepsis Study G (2008) Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 299(19):2294–2303
38. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 36(2):222–231
39. Shapiro NI, Howell MD, Talmor D, Nathanson LA, Lisbon A, Wolfe RE, Weiss JW (2005) Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 45(5):524–528
40. Garcia-Alvarez M, Marik P, Bellomo R (2014) Sepsis-associated hyperlactatemia. Crit Care 18(5):503
41. Holmboe M, Giske CG, Fredriksen M, Ostholm Balkhed A, Claesson C, Nilsson LE, Hoffmann M, Hanberger H (2016) 14-year survey in a Swedish County reveals a pronounced increase in bloodstream infections (BSI). Comorbidity—an independent risk factor for both BSI and mortality. PLoS One 11(11):e0166527
42. Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, Honrubia T, Algara A, Bustos A, Garcia G, Diaz-Regan IR, de Luna RR (2007) Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med 35(5):1284–1289
43. Goto M, Al-Hasan MN (2013) Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 19(6):501–509
44. Shapiro N, Howell MD, Bates DW, Angus DC, Ngo L, Talmor D (2006) The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med 48(5):583–590 e581
45. Sanderson M, Chikhiani M, Blyth E, Wood S, Moppeit IK, McKeever T, Simmonds MJ (2018) Predicting 30-day mortality in patients with sepsis: an exploratory analysis of process of care and patient characteristics. J Intensive Care Soc 19(4):299–304
46. Godfrey G, Pilcher D, Hilton A, Bailey M, Hodgson CL, Bellomo R (2012) Treatment limitations at admission to intensive care units in Australia and New Zealand: prevalence, outcomes, and resource use*. Crit Care Med 40(7):2082–2089
47. Skjærek SA, Hoel H, Dahl V, Stavem K (2017) Factors associated with life-sustaining treatment restriction in a general intensive care unit. PLoS One 12(7):e0181312

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.